Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds - PubMed
4 hours ago
- #Personalized Medicine
- #Non-cytokine Therapies
- #Inflammatory Bowel Disease
- Cytokine-targeted therapies are insufficient for some IBD patients, leading to the development of non-cytokine therapies.
- Non-cytokine therapies target pathways like immune cell trafficking, intracellular signaling, and lymphocyte recirculation.
- Major therapy categories include anti-integrin agents, JAK-STAT inhibitors, and S1P receptor modulators.
- These therapies offer new options for treatment-refractory disease and enable combination strategies.
- Precision medicine approaches, including immune phenotyping and biomarker development, are needed to optimize treatment.